FDA to review Gattex

FDA accepted for review an NDA from NPS Pharmaceuticals Inc. (NASDAQ:NPSP) for Gattex teduglutide to treat short bowel syndrome (SBS). NPS, which requested Priority Review, said it expects FDA to assi...